Compare Biogen Inc (BIIB) vs Blackstone Inc (BX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Blackstone Inc — how do they compare? Biogen Inc trades at $207.01 (market cap $30.13B), while Blackstone Inc trades at $145.92 (market cap $117.44B). The key difference: Blackstone Inc is far larger — about 3.9× Biogen Inc's market cap, and Blackstone Inc pays a 3.55% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | BX | |
|---|---|---|
Market Cap | $30.13B | $117.44B |
Sector | Health | Financials |
52-Week High | $216.63 | $188.68 |
52-Week Low | $128.93 | $102.12 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Blackstone (BX) trades at $145.65, up 2.81% today, with strong technical momentum showing bullish moving averages and approaching resistance at $147. The company demonstrates robust fundamentals with revenue growth from $10.9B in 2024 to $12.4B in 2025 and net income margin of 25.85%. Recent acquisitions including the Aeroplan stake and HSBC's Australian loan portfolio highlight strategic expansion.
Outlook remains positive with analyst consensus at Buy (63%) and $144 price target, though RSI levels suggest potential overbought conditions. Key risks include private credit market strain and integration challenges from recent acquisitions. Earnings consistency with three consecutive beats supports the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Blackstone Inc
Blackstone is one of the world's largest alternative asset managers with $940.8 billion in total asset under management, including $683.8 billion in fee-earning asset under management, at the end of June 2022.
Read more on BX →
